Journal article
Phase I study of allogeneic monocyte-derived inflammatory dendritic cells in combination with pembrolizumab
Future science OA, Vol.10(1), 2426426
12/01/2024
DOI: 10.1080/20565623.2024.2426426
PMCID: PMC11581178
PMID: 39563512
Abstract
PD-1 checkpoint inhibition has revolutionized the care of cancer. A small portion of patients with stage IV cancer achieve durable control. But, early progression is common and dramatic control is achieved for only a minority. We hypothesized that ilixadencel, an allogeneic monocyte-derived dendritic cell product could be injected into tumor to potentiate PD-1 response and thus conducted a phase I study of pembrolizumab plus ilixadencel. Twenty-one patients were accrued. The most common treatment emergent adverse events were fatigue, injection site pain, anemia, weight decreased and hyponatremia, mostly grade 1-2. No dose limiting toxicities were observed and the recommended phase II dose was established at 10 million cells administered twice. Two unconfirmed responses were observed, with no confirmed responses.
Immunotherapy is an exciting new type of cancer medicine that uses the body’s own immune system to attack cancer. A small number of patients with stage IV cancers are even cured with immunotherapy. We tried to increase the number of patients with dramatic benefit by adding an experimental immunotherapy, called ilixadencel to approved immunotherapy. Ilixadencel is an immune cell type called “dendritic cells” which were injected directly into tumors. While we did show ilixadencil to be safe, efficacy was limitted.
Details
- Title: Subtitle
- Phase I study of allogeneic monocyte-derived inflammatory dendritic cells in combination with pembrolizumab
- Creators
- Jared Weiss - University of North Carolina at Chapel HillDouglas Laux - University of IowaDavid Bajor - University Hospitals of ClevelandAlbert C. Lockhart - MUSC Hollings Cancer CenterJohn Hamm - Norton HealthcareJeroen Rovers - Mendus ABAlex Karlsson-Parra - Mendus AB
- Resource Type
- Journal article
- Publication Details
- Future science OA, Vol.10(1), 2426426
- DOI
- 10.1080/20565623.2024.2426426
- PMID
- 39563512
- PMCID
- PMC11581178
- NLM abbreviation
- Future Sci OA
- ISSN
- 2056-5623
- eISSN
- 2056-5623
- Publisher
- Taylor & Francis; ABINGDON
- Grant note
- Mendus
This work was funded by Mendus.
- Language
- English
- Date published
- 12/01/2024
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984749733902771
Metrics
2 Record Views